 |
|
|
| |
Access to hepatitis C treatment in Europe: findings from
the 2016 Hep-CORE study
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
JV Lazarus1,2, SR Stumo2, K Safreed-Harmon2, FH Harmanci3, M Harris4, G Hendrickx5, M Jauffret-Roustide6, T Reic7, J Tallada8, M Maticic9, on behalf of the
Hep-CORE Study Group
1CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 2ISGlobal, Hospital Clínic, University of Barcelona, Barcelona, Spain; 3Global Hepatitis Programme, World Health Organization, Geneva, Switzerland; 4Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, London, United Kingdom; 5Viral HepatitisPrevention Board, University of Antwerp, Antwerp, Belgium; 6Cermes3, Inserm, Paris Descartes University, Paris, France; 7European Liver Patients Association, Brussels, Belgium; 8European AIDS Treatment Group, Brussels, Belgium; 9Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, Slovenia
EASL: Restrictions for reimbursement of interferon-free direct acting antiviral therapies for HCV infection in Europe - (05/15/17)
|
| |
|
|
|
|
|
